Celexa Lawsuit

Schmidt & Clark, LLP is No Longer Taking These Cases - If you feel that you may have a potential case, we urge you to contact another law firm adequately suited to handle your case.

SSRI antidepressants including the popular drugs Celexa, Cipramil, Emocal, Sepram, Seropram (Generic: citalopram) have been linked to variety of severe birth defects including Persistent Pulmonary Hypertension (PPHN), heart, lung, abdominal and cranial defects.

Celexa is an FDA-approved prescription medication used to treat depression and other serious psychological disorders. The drug belongs to a class of antidepressants called selective serotonin reuptake inhibitors (SSRIs). Celexa is made by Forest Labs, and was approved by the U.S. Food & Drug Administration (FDA) in July 1998.

FDA Video: SSRI Antidepressant Birth Defects

Below is an excellent video produced by the U.S. Food & Drug Administration (FDA), which warns patients and physicians of serious, life-threatening birth defects linked to SSRI antidepressants.

Read the Full Transcript: SSRI Antidepressant Birth Defects

Congenital Heart Defects

The U.S. Food & Drug Administration has warned doctors and patients that exposure to SSRI’s such as Celexa during pregnancy pose a serious risk to the fetus and has been linked to an increased risk of Congenital Heart Defects.

More specifically, the most common form of Celexa induced heart birth defects observed by our firm has been either Atrial Septal Defects or Ventricular Septal Defects.

Persistent Pulmonary Hypertension of the Newborn (PPHN)

Recently, The New England Journal of Medicine released the results of a case-controlled study wherein SSRI’s including Celexa were linked to an increased risk of an infant being born with Persistent Pulmonary Hypertension of the Newborn (PPHN).

Shortly after the aforementioned study was released, the FDA issued another Public Health Advisory warning that exposure to Celexa during pregnancy posed a serious risk to the fetus and was linked to an increased risk of PPHN.

Abdominal & Cranial Birth Defects

According to information released from the National Birth Defects Prevention Study of Infants, SSRI antidepressants like Celexa may cause two separate congenital abnormalities called Omphalocele and Craniosynostosis.

Omphalocele is a congenital (present at birth) abdominal wall defect at the base of the umbilical cord (umbilicus); the infant is born with a sac protruding through the defect which contains small intestine, liver, and large intestine.

Craniosynostosis is a congenital (present at birth) defect that causes one or more sutures on a baby’s head to close earlier than normal. Sutures are connections that separate each individual skull bones. The early closing of a suture leads to an abnormally shaped head.

Known Celexa Side Effects

  • Withdrawal
  • Birth Defects
  • Congenital Heart Defects, Atrial or Ventricular Septal Defects (hole in heart)
  • Persistent Pulmonary Hypertension of the Newborn (PPHN)
  • Abdominal Birth Defects / Omphalocele
  • Cranial Birth Defects / Craniosynostosis

Birth Defects Linked to Antidepressants

12 Celexa Lawsuits Filed in West Virginia

Twelve new lawsuits have been entered in Cabell Circuit Court on behalf of children who were allegedly born with congenital defects after their mothers took Celexa and/or Lexapro in pregnancy, according to the West Virginia Record. The suits maintain that both Celexa and Lexapro contain the same active ingredient, making them basically the same drug. Plaintiffs allege that Forest knew or should have known about the antidepressants’ ability to cause birth defects, and that the company aggressively marketed Lexapro and Celexa to women in their childbearing years, including to pregnant women. Click here to learn more.

Judge Dismisses Suit in Celexa Marketing MDL

A lawsuit against Forest Pharmaceuticals has been thrown out, and another had a state law claim trimmed, in the ongoing multidistrict litigation (MDL) accusing the company of marketing Lexapro and Celexa to children, even though the antidepressants had not been approved for that purpose. On Dec. 14, 2014, U.S. District Judge Nathaniel M. Gorton ruled that Allied Services Division Welfare Fund, New Mexico UFCW unions and Employers Health and Welfare Trust Fund knew about Forest’s allegedly illegal marketing of Lexapro and Celexa since at least 2009, and that their March 2014 lawsuit is invalid due to statute of limitations (SOL) concerns. Click here to learn more.

Awards & recognition